GROSS LAW FIRM

MOLN LAWSUIT: Molecular Partners Loss Submission Form

The Gross Law Firm notifies investors that a class action has commenced in the United States District Court for the Southern District of New York on behalf of shareholders of Molecular Partners AG who purchased : (a) American Depositary Shares pursuant and/or traceable to certain documents issued in connection with the Company’s initial public offering conducted on or about June 16, 2021; and/or (b) securities between June 16, 2021, and April 26, 2022.

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that:

(i) the Company’s product, ensovibep, was less effective at treating COVID-19 than defendants had led investors to believe; that (ii) accordingly, the the U.S. Food and Drug Administration (“FDA”) was reasonably likely to require an additional Phase 3 study of ensovibep before granting the drug Emergency Use Authorization (“EUA”); (iii) waning global rates of COVID-19 significantly reduced the Company’s chances of securing EUA for ensovibep; (iv) another of the Company’s product candidates, MP0310, was less attractive to Molecular Partners’ collaborator, Amgen, than defendants had led investors to believe; (v) accordingly, there was a significant likelihood that Amgen would return to global rights of MP0310 to Molecular Partners; (vi) as a result of all the foregoing, the clinical and commercial prospects of ensovibep and MP0310 were overstated; and (vii) as a result, documents issues in connection with the Company’s initial public offer and defendants’ public statements throughout the class period were materially false and/or misleading and failed to state information required to be stated therein.

If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the respective securities during the class periods. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action. Appointment as Lead Plaintiff is not required to partake in any recovery.

Shareholders have until September 12, 2022 to request that the court appoint them lead plaintiff.

To receive more information, please fill out the form.

Name

Email

Physical Address

Phone Number

Shares Owned

Purchase Date

Loss

By submitting your information, it does not create an attorney-client relationship and you are giving us your express consent to contact you by email, text message, SMS, or call you by telephone.

Privacy Notice